Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Maintenance Therapy with Daratumumab ± Pomalidomide Following Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: Results from a Phase 2 Trial

  • By

  • Oren Pasvolsky

  • Bruno Almeida Costa

  • Yosra M. Aljawai

  • Krina K. Patel

  • Qaiser Bashir

  • Dawen Sui

  • Samer A. Srour

  • Mark R. Tanner

  • Uday R. Popat

  • Neeraj Y. Saini

  • Chitra Hosing

  • Jeremy L. Ramdial

  • Hans C. Lee

  • Gregory P. Kaufman

  • Sheeba K. Thomas

  • Donna M. Weber

  • Melody Becnel

  • Guilin Tang

  • Robert Z. Orlowski

  • Richard E. Champlin

  • Yago Nieto

  • Elizabeth J. Shpall

  • Muzaffar H. Qazilbash

  • September 26, 2026

Share

  • 1

    A phase 2 trial evaluated daratumumab with or without pomalidomide as maintenance therapy after salvage autologous stem cell transplantation in relapsed multiple myeloma.

  • 2

    The study included 13 patients, with a median age of 64 years and a median of 2 prior therapy lines before salvage ASCT.

  • 3

    At 4 years post-salvage ASCT, progression-free survival was 62%, while overall survival reached 100%.

  • 4

    Response rates improved during maintenance, with 85% of patients achieving complete response or better by the final assessment.

  • 5

    Neutropenia was the most common grade ≥3 adverse event, affecting 62% of patients during the study.

Original Source(s)

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

  • by Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel, Qaiser Bashir, Dawen Sui, Samer A. Srour, Mark R. Tanner, Uday R. Popat, Neeraj Y. Saini, Chitra Hosing, Jeremy L. Ramdial, Hans C. Lee, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Guilin Tang, Robert Z. Orlowski, Richard E. Champlin, Yago Nieto, Elizabeth J. Shpall, Muzaffar H. Qazilbash

  • September 26, 2026

Related Content

Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min
Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI